Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Cerebrospinal fluid circulating tumor cells: a novel tool to diagnose leptomeningeal metastases from epithelial tumors.

Lin X, Fleisher M, Rosenblum M, Lin O, Boire A, Briggs S, Bensman Y, Hurtado B, Shagabayeva L, DeAngelis LM, Panageas KS, Omuro A, Pentsova EI.

Neuro Oncol. 2017 Sep 1;19(9):1248-1254. doi: 10.1093/neuonc/nox066.

2.

EpCAM-based flow cytometry in cerebrospinal fluid greatly improves diagnostic accuracy of leptomeningeal metastases from epithelial tumors.

Milojkovic Kerklaan B, Pluim D, Bol M, Hofland I, Westerga J, van Tinteren H, Beijnen JH, Boogerd W, Schellens JH, Brandsma D.

Neuro Oncol. 2016 Jun;18(6):855-62. doi: 10.1093/neuonc/nov273. Epub 2015 Nov 12.

3.

EpCAM-based assays for epithelial tumor cell detection in cerebrospinal fluid.

van Bussel MTJ, Pluim D, Bol M, Beijnen JH, Schellens JHM, Brandsma D.

J Neurooncol. 2018 Mar;137(1):1-10. doi: 10.1007/s11060-017-2691-6. Epub 2017 Nov 30. Review.

PMID:
29192390
4.

Rare cell capture technology for the diagnosis of leptomeningeal metastasis in solid tumors.

Nayak L, Fleisher M, Gonzalez-Espinoza R, Lin O, Panageas K, Reiner A, Liu CM, Deangelis LM, Omuro A.

Neurology. 2013 Apr 23;80(17):1598-605; discussion 1603. doi: 10.1212/WNL.0b013e31828f183f. Epub 2013 Apr 3.

5.

Detection of cerebrospinal fluid tumor cells and its clinical relevance in leptomeningeal metastasis of breast cancer.

Lee JS, Melisko ME, Magbanua MJ, Kablanian AT, Scott JH, Rugo HS, Park JW.

Breast Cancer Res Treat. 2015 Nov;154(2):339-49. doi: 10.1007/s10549-015-3610-1. Epub 2015 Oct 31.

PMID:
26520840
6.

CSF protein profiling using Multiplex Immuno-assay: A potential new diagnostic tool for leptomeningeal metastases.

Brandsma D, Voest EE, de Jager W, Bonfrer H, Algra A, Boogerd W, Korse T, Reijneveld JC, Verbeek MM, Rijkers G, Taphoorn MJ.

J Neurol. 2006 Sep;253(9):1177-84. Epub 2006 Sep 22.

PMID:
16998648
7.

Detection and quantification of CSF malignant cells by the CellSearch technology in patients with melanoma leptomeningeal metastasis.

Le Rhun E, Tu Q, De Carvalho Bittencourt M, Farre I, Mortier L, Cai H, Kohler C, Faure GC.

Med Oncol. 2013 Jun;30(2):538. doi: 10.1007/s12032-013-0538-3. Epub 2013 Mar 16.

PMID:
23504338
8.

The diagnostic accuracy of magnetic resonance imaging and cerebrospinal fluid cytology in leptomeningeal metastasis.

Straathof CS, de Bruin HG, Dippel DW, Vecht CJ.

J Neurol. 1999 Sep;246(9):810-4.

PMID:
10525979
9.

Diagnostic Value of CYFRA 21-1 in the Cerebrospinal Fluid for Leptomeningeal Metastasis.

Zhang Z, Tian C, Shi Q, Hao J, Zhao N, Liu Z.

Dis Markers. 2017;2017:2467870. doi: 10.1155/2017/2467870. Epub 2017 Feb 19.

10.

SHP-1 promoter 2 methylation in cerebrospinal fluid for diagnosis of leptomeningeal epithelial-derived malignancy (carcinomatous meningitis).

Vinayanuwattikun C, Mingmalairak S, Jittapiromsak N, Thaipisuttikul I, Sriuranpong V, Mutirangura A, Shuangshoti S.

J Neurooncol. 2016 Sep;129(3):395-403. doi: 10.1007/s11060-016-2199-5. Epub 2016 Jul 11.

PMID:
27401153
11.

Thinprep plus Papanicolaou stain method is more sensitive than cytospin-coupled Wright Giems stain method in cerebrospinal fluid cytology for diagnosis of leptomeningeal metastasis from solid tumors.

Pan Z, Yang G, Wang Y, He H, Pang X, Gao Y, Shi W, Li Y, Dong L, Song Y.

PLoS One. 2015 Apr 7;10(4):e0122016. doi: 10.1371/journal.pone.0122016. eCollection 2015.

12.

CellSearch technology applied to the detection and quantification of tumor cells in CSF of patients with lung cancer leptomeningeal metastasis.

Tu Q, Wu X, Le Rhun E, Blonski M, Wittwer B, Taillandier L, De Carvalho Bittencourt M, Faure GC.

Lung Cancer. 2015 Nov;90(2):352-7. doi: 10.1016/j.lungcan.2015.09.008. Epub 2015 Sep 14.

PMID:
26386833
13.

Overexpression of syndecan-1, MUC-1, and putative stem cell markers in breast cancer leptomeningeal metastasis: a cerebrospinal fluid flow cytometry study.

Cordone I, Masi S, Summa V, Carosi M, Vidiri A, Fabi A, Pasquale A, Conti L, Rosito I, Carapella CM, Villani V, Pace A.

Breast Cancer Res. 2017 Apr 11;19(1):46. doi: 10.1186/s13058-017-0827-4.

14.

CSF levels of growth factors and plasminogen activators in leptomeningeal metastases.

van de Langerijt B, Gijtenbeek JM, de Reus HP, Sweep FC, Geurts-Moespot A, Hendriks JC, Kappelle AC, Verbeek MM.

Neurology. 2006 Jul 11;67(1):114-9.

PMID:
16832089
15.

A comparison between ventricular and lumbar cerebrospinal fluid cytology in adult patients with leptomeningeal metastases.

Chamberlain MC, Kormanik PA, Glantz MJ.

Neuro Oncol. 2001 Jan;3(1):42-5. doi: 10.1093/neuonc/3.1.42.

16.

Leptomeningeal metastases in the MRI era.

Clarke JL, Perez HR, Jacks LM, Panageas KS, Deangelis LM.

Neurology. 2010 May 4;74(18):1449-54. doi: 10.1212/WNL.0b013e3181dc1a69.

17.

Leptomeningeal metastasis: Clinical experience of 519 cases.

Hyun JW, Jeong IH, Joung A, Cho HJ, Kim SH, Kim HJ.

Eur J Cancer. 2016 Mar;56:107-114. doi: 10.1016/j.ejca.2015.12.021. Epub 2016 Feb 1.

PMID:
26841095
18.

Imaging features of leptomeningeal metastases.

Collie DA, Brush JP, Lammie GA, Grant R, Kunkler I, Leonard R, Gregor A, Sellar RJ.

Clin Radiol. 1999 Nov;54(11):765-71.

PMID:
10580769
19.

Leptomeningeal metastases: a RANO proposal for response criteria.

Chamberlain M, Junck L, Brandsma D, Soffietti R, Rudà R, Raizer J, Boogerd W, Taillibert S, Groves MD, Le Rhun E, Walker J, van den Bent M, Wen PY, Jaeckle KA.

Neuro Oncol. 2017 Apr 1;19(4):484-492. doi: 10.1093/neuonc/now183. Review.

20.

CSF CA 15-3 in breast cancer-related leptomeningeal metastases.

Le Rhun E, Kramar A, Salingue S, Girot M, Rodrigues I, Mailliez A, Zairi F, Bakhache E, Robin YM, Taillibert S, Dubois F, Bonneterre J, Chamberlain MC.

J Neurooncol. 2014 Mar;117(1):117-24. doi: 10.1007/s11060-014-1361-1. Epub 2014 Jan 28.

PMID:
24469852

Supplemental Content

Support Center